Argus Research Rates Zimmer Biomet (ZBH) Buy, $125 Price Target
Key Points
- Argus Research maintained its Buy rating on Zimmer Biomet Holdings, Inc. on October 22, 2026, holding its price target steady at $125.00.
- Argus Research's $125 price target implies 28.42% upside from Zimmer Biomet Holdings, Inc.'s ($ZBH) current $97.33 share price.
- Zimmer Biomet shares recently traded around $97.33, sitting up about 2.3% above their 50-day moving average as the company prepares for its upcoming November 4 earnings report.
- Major institutional funds hold substantial stakes in the medical technology company, with Dodge & Cox Inc. ending its recent report period with 24,124,735 shares.
Get Zimmer Biomet Holdings text alerts
We text you when insiders, Congress, analysts or big funds move on $ZBH.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Zimmer Biomet Holdings, Inc. alert may contain errors. Disclosures
On October 22, 2026, Argus Research maintained its Buy rating on Zimmer Biomet Holdings, Inc. and kept its price target steady at $125.00. The research note provides a forward-looking opinion on the medical device maker as shares change hands near the $97.33 mark. Argus left its target unchanged from a previous level of $125.00.
ZBH
Zimmer Biomet Holdings, Inc.
Argus Research's Call on Zimmer Biomet Holdings, Inc.
On October 22, 2026, Argus Research maintained its Buy rating on Zimmer Biomet with a price target of $125.00. This update adds to a busy stretch of analyst adjustments for the healthcare company heading into its next financial reporting date.
Other Institutional Activity in Zimmer Biomet Holdings, Inc.
Large investment firms have adjusted their positions in the medical technology company over recent reporting periods. Dodge & Cox Inc. grew its holdings by 581,517 shares, ending with 24,124,735 shares worth about $2,366,757,208.0. Harris Associates L.P. reduced its stake by 221,610 shares, wrapping up the period with 12,738,025 shares valued at roughly $1,249,663,985.0. Meanwhile, Capital International Investors boosted its position by 3,064,142 shares, or 33.6%, bringing its total count to 12,183,614 shares worth about $1,195,273,492.0.
Zimmer Biomet Holdings, Inc. Stock Up 2.6%
Zimmer Biomet shares recently traded around $97.33 as of October 22, 2026. The stock sits up about 2.3% above its 50-day moving average of $95.16 and roughly 6.4% above its 200-day moving average of $91.45. The recent price trades below the 52-week high of $104.15 and well above the 52-week low of $79.12.
$ZBH price target
Zimmer Biomet Holdings, Inc. daily closes and this analyst's $125 target. Not advice.
Recent Earnings
The medical device maker posted a trailing-twelve-month revenue of $8,508,800,000.0 with earnings of $4.12 per share. The company records a net profit margin of 9.5% and a return on equity of 6.4%. Investors look ahead to the next earnings announcement scheduled for November 4, 2026.
Dividend
Zimmer Biomet pays an annual dividend rate of $0.96 per share, which translates to a dividend yield of 1.01%. The company distributes 23.3% of its earnings as dividends to shareholders.
Insider Buying and Selling at Zimmer Biomet Holdings, Inc.
Company officers completed several stock sales earlier in the year. Lori Winkler sold 2,650 shares on March 12, 2026, at an average price of $94.66 for a total value of $250,849.0. Sang Yi parted with 5,000 shares on May 29, 2026, totaling $413,216.0. Chad F Phipps disposed of 3,000 shares on September 4, 2026, at $98.35 per share for a total value of $295,050.0. Kevin R Thornal sold 5,691 shares on September 11, 2026, at $92.95 per share, realizing about $528,978.0.
Analysts Set New Price Targets
Wall Street firms have actively updated their views on the stock through the late summer and fall. On August 6, 2026, RBC Capital maintained an Outperform rating and raised its target from $101.0 to $110.0. Truist Securities kept a Hold rating on August 7, 2026, lifting its target to $106.0 from $92.0. Canaccord Genuity maintained a Hold rating on August 10, 2026, while moving its target from $83.0 to $100.0. Barclays initiated coverage on October 7, 2026, with an Equal-Weight rating and a $100.0 target. Across the broader analyst community, the stock holds a consensus buy recommendation with a mean price target of $106.90 based on 21 analyst opinions.
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. operates as a medical technology company that designs and markets orthopedic reconstructive products, knee and hip replacements, and surgical solutions worldwide. Headquartered in Warsaw, Indiana, the firm employs 17,000 people and serves hospitals and healthcare providers globally.
Bottom Line
Argus Research continues to show confidence in Zimmer Biomet with its reaffirmed Buy rating and $125.00 price target. Market participants will monitor the upcoming earnings report on November 4, 2026, for further updates on financial performance and product demand.
Related Filing Alerts
Source: Argus Research's rating change on $ZBH (Oct 22, 2026). Written by software, not financial advice. How we make alerts